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                    Takao OsADA， Takeo INouE， Osamu KuDo，
                      Koichi KuRoKo and Masaharu Yosmo
        From the DePartment of UrologJ， St． Marianna Universit） Schoog of Medicine， Kawasaki
                             （Dire・t・r・ P・φ乃勧伽・ノ
    Urinary hydroxyproline has been attracted attention as an early index of bony metastasis in
carcinoma’盾?the prostate． We estimated urinary hydroxyproline excretion in patients with carcinoma
of the prostate and the following results were obtained．
    （1） Hydroxyproline measurements in 24－hour urine samples of 23 normal male adults were done
in order to deterrnine the normal value．
    The． results indicated thqt 24－hour urinary hydroxyproline output was 30．7土7．1 mg／day（mean±
SD） and 24－hour urinary hydroxyproline／creatinine ratio was 24．6±3．7 mgfg （mean±SD）．
    （2） Both 24－hour urinary hydroxyproline excretion and hydroxyproline／creatinine ratio were
elevated in patients with carcinolna of the prostate with osseous mctastasis whcn co皿pared・to those
ofエ10rmal male adults， patients with benign prostatic hypertrophy and patients with carcinoma of
the prostate without osseous metastasis （P〈O．Ol）．
    （3） Both 24－hour urinary hydroxyproline excretion and hydroxyproline／creatinine ratio tended
to decrease in patients with carcinoma of the prostate with osseous metastasis who were responding
favorably to hormonal manipulation．
    （4） Hydroxyproline and hydroxyproline／creatinine ratio in ．an early morning urine and a spot
urine were well c6rrelated with those in 24－hour urine， thus， an early morning urine or a spot urine
could be the specimen．
   This results presented here indicate that urinary hydroxyproline excretion may be a sensitive
tumor marker 6f bony metastasis in carcinoma of the prostate．
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Fig． 2． Urinary hydroxyproline excretion in
    benign prostatic hypertrophy patients
    and untreated prostatic cancer patients
    with and without osseou smetastasis
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Fig． 3． Mean value of urinary hydroxyproline
    excretion jn prostatic cancer patients
    with and without skeletal metastasis：
    Comparison o£ untreated cases to those
    treated with estrogen































































Fig． 4． Urinary hydroxyproline excretion in
    benign prostatic hypertrophy patients
    andLuntreated prostatic cancer patients
    with and without osseous metastasis

















































































Fig． 5． Mean value of urinary hydroxyproline
    excretion in prostatic cancer patients
    with and without osseous metastasis ：
    Comparison of untreated cases to those
    treated with estrogen
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Fig．6． uri職ry hydroxyproline excretion expressed as output in mg／day and as output三n mg／9
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Fig． 7． Correlation between 24－hour and early
    morning urine （EMU） sample expres－
    sed as output in hydroxyproline mg／g




























増加しており，false ncgativeは少なく， stage Dで
もT4 M・一4 Moでは増加しているものが少なく，
false Positiveも少数で， stage CやB，それ｝こ二三患








































では，Bishop and Fcllows5）15～43 mg／day， Kont－
turiら4）15～60 mg／day， Mundyl o）15～45 mg／dayで
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